Angle prostate cancer test sees shares rocket

Angle, the Surrey-based technology investment firm, has seen its share price rocket nearly 15% on news one of its divisions has found a new way to detect prostate cancer.

Parsortix, which is 90% owned by Angle, claims its "separation technology" can capture prostate cancer cells added to blood.

The will allow for the early detection of cancer and the monitoring of patients both during and after treatment.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Angle Founder and Chief Executive, Andrew Newland, commented: "The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable."

At 09:45, Angle shares were trading at 89.5p, up 14.5% (10.51p).

BS